Companies XBiotech Inc.
XBiotech (XBIT): executive pay, fiscal 2025
Free brief. Every figure links to the company’s own filing.
Email me XBiotech Inc.’s executive pay brief as a PDF
It arrives in about 2 minutes, with every figure cited to its filing.
After the PDF, up to three short notes on the deeper reports for this company. Reply “unsubscribe” to any of them, any time.
CEO pay, last three years
- $720,499FY2023
- $657,572FY2024
- $570,992FY2025
CEO total pay was $570,992 in fiscal 2025, down from $657,572 in fiscal 2024.
FY2025: salary $468,557 · bonus $90,000 · stock awards $0 · option awards $0
Order XBIT
Add the email the receipt and the PDF go to, then press the report you want. Each button opens its own card payment on Stripe.
Full detail
Every table from the filing. Open any section.
Summary compensation table
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| John Simard | $1,250,000 | $8,530,442 | — | $3,000,000 | — | — | $17,353,762 | $30,134,204 |
| Former President & Chief Executive Officer | ||||||||
| Sushma Shivaswamy | 468,557 | 90,000 | 0 | 0 | 0 | 0 | 12,436 | 570,992 |
| Interim Chief Executive Officer & Chief Scientific Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
Three-year trend — total compensation per named executive
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| John Simard | $30,134,204 | $6,245,581 | $5,556,481 | ↑ +23,888,623 |
| Sushma Shivaswamy | 570,992 | 657,572 | 720,499 | ↓ −86,580 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Incentive-plan design — the Compensation Discussion & Analysis
The Company's executive compensation program is designed to attract and retain key executives critical to the Company's success and to align the financial interests of executive officers with those of shareholders. The program seeks to motivate and reward executives by ensuring that a significant portion of compensation opportunities is directly related to the achievement of financial and operational goals that impact shareholder value.
| CEO STI target (% of salary) | — |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | — |
| Clawback policy | true |
| Anti-hedging | true |
| Anti-pledging | true |
Equity grants and outstanding awards
No plan-based awards are on file for this fiscal year.
Outstanding equity awards at fiscal year-end 2025
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Hu | Option | 5,000 | 5.26 | — |
| Hu | Option | 10,000 | 10.36 | — |
| Hu | Option | 10,000 | 12.64 | — |
| Sushma Shivaswamy | Option | 15,000 | 5.26 | — |
| Hu | Option | 30,000 | 3.84 | — |
| John Simard | Option | 48,125 | 9.45 | — |
| Sushma Shivaswamy | Option | 50,000 | 4.24 | — |
| John Simard | Option | 61,516 | 4.24 | — |
| Sushma Shivaswamy | Option | 100,000 | 3.84 | — |
| Sushma Shivaswamy | Option | 100,000 | 10.36 | — |
| Sushma Shivaswamy | Option | 100,000 | 12.67 | — |
| John Simard | Option | 110,740 | 4.44 | — |
| Sushma Shivaswamy | Option | 150,000 | 4.13 | — |
| John Simard | Option | 150,000 | 7.45 | — |
| John Simard | Option | 500,000 | 11.12 | — |
| John Simard | Option | 1,026,228 | 3.52 | — |
Director compensation
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Craig RademakerIndependent · Newly elected | $73,260 | — | $163,156 | — | — | $236,417 |
| Thomas KündigIndependent · Newly elected | 62,795 | — | 140,147 | — | — | 202,942 |
| Tevi TroyIndependent | 33,973 | — | 99,200 | — | 0 | 133,173 |
| Jan-Paul WaldinIndependent · Not standing for re-election · Departed during FY | 105,644 | — | 23,976 | — | 0 | 129,620 |
| David SofferIndependent | 30,575 | — | 90,343 | — | — | 120,919 |
| Peter LibbyIndependent · Not standing for re-election · Departed during FY | 85,836 | — | 23,976 | — | 0 | 109,812 |
| Tak MakIndependent · Not standing for re-election · Departed during FY | 46,219 | — | 23,976 | — | 0 | 70,195 |
| W.Thorpe McKenzieIndependent · Not standing for re-election · Departed during FY | 32,986 | — | 0 | — | 0 | 32,986 |
| John SimardIndependent · Board Chair | — | — | — | — | — | — |
Board fee structure and ownership guideline
| Annual cash retainer | $50,000 |
|---|---|
| Annual equity retainer | — |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | — |
| Stock ownership guideline | — |
Total cost of the board
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $471,288 |
| Equity awards (grant-date value) | $0 |
| All other compensation | $0 |
| Total cost of the board | $471,288 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Peer group, and who names XBiotech as a peer
Companies that benchmark against XBIT
1 company names XBIT as a compensation peer
- Amylyx Pharmaceuticals, Inc.AMLXFY2025
Each company listed discloses XBIT in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named XBIT in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.
Chief executive pay against the peer group
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company’s own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | XBiotech Inc. | 2025 | Sushma Shivaswamy | $468,557 | $0 | $0 | $0 | $570,992 |
Each peer’s compensation is from its most recently filed proxy; fiscal years differ by company. Each peer’s figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Say-on-pay history and pay ratio
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2025 | 2025-08-29 | 11,336,500 | 1,460,498 | 68,134 | 88.59% | Passed |
| 2019 | 2019-06-19 | — | — | — | — | — |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year’s compensation.
Say-on-pay — history, company’s computation
| Meeting year | Meeting date | Approval — company’s computation |
|---|---|---|
| 2025 | 2025-08-29 | 88.59%a |
| 2019 | 2019-06-19 | —b |
a. Voting standard not stated in the filing.
b. Voting standard not stated in the filing.
Approval percentages are the company’s own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
CEO pay ratio
| Ratio (CEO : median employee) | 55 : 1 |
|---|---|
| CEO total compensation | — |
| Median employee compensation | $100,548 |
Insider trades since the proxy
No insider equity transactions reported since the proxy statement.
Sources (17 citations)
Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.
- Section 01, John Simard. DEF 14A, filed 2026-10-02. Section “Executive Compensation”. As printed: 30,134,204. View filing ↗
- Section 01, Sushma Shivaswamy. DEF 14A, filed 2026-10-02. Section “Executive Compensation”. As printed: 570,992. View filing ↗
- Section 07, pay ratio. DEF 14A, filed 2024-05-01. Section “CEO Pay Ratio”. As printed: 55 : 1. View filing ↗
- Section 08, Craig Rademaker. DEF 14A, filed 2026-10-02. Section “Director Compensation”. As printed: 236,417. View filing ↗
- Section 08, Thomas Kündig. DEF 14A, filed 2026-10-02. Section “Director Compensation”. As printed: 202,942. View filing ↗
- Section 08, Tevi Troy. DEF 14A, filed 2026-10-02. Section “Director Compensation”. As printed: 133,173. View filing ↗
- Section 08, Jan-Paul Waldin. DEF 14A, filed 2026-10-02. Section “Director Compensation”. As printed: 129,620. View filing ↗
- Section 08, David Soffer. DEF 14A, filed 2026-10-02. Section “Director Compensation”. As printed: 120,919. View filing ↗
- Section 08, Peter Libby. DEF 14A, filed 2026-10-02. Section “Director Compensation”. As printed: 109,812. View filing ↗
- Section 08, Tak Mak. DEF 14A, filed 2026-10-02. Section “Director Compensation”. As printed: 70,195. View filing ↗
- Section 08, W.Thorpe McKenzie. DEF 14A, filed 2026-10-02. Section “Director Compensation”. As printed: 32,986. View filing ↗
- Section 08, John Simard. DEF 14A, filed 2026-10-02. Section “Director Compensation”. As printed: —. View filing ↗
- Section 06, 2025 vote. Form 8-K, filed 2025-09-02. Item 5.07 · say-on-pay result. As reported: 88.59% (votes for as printed: 11,336,500). View filing ↗
- Section 06, 2019 vote. Form 8-K, filed 2019-06-20. Item 5.07 · say-on-pay result. As reported: —. View filing ↗
- Section 01 trend, Δ column (computed). Computed. Δ = current-FY total − prior-FY total per named officer.
- Section 09b board cost (computed). Computed. Cash 471,288 + equity 0 + all other 0 = 471,288, summed across the director compensation table rows.
- XBiotech Inc. (subject), Section 10b CEO total. DEF 14A, filed 2026-10-02. CEO total compensation as printed in XBiotech Inc.'s own proxy. As printed: 570,992. View filing ↗